J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push

Vandana Singh

Tue, February 24, 2026 at 7:45 PM GMT+9 2 min read

In this article:

JNJ

+1.38%

**Johnson & Johnson **(NYSE:JNJ) is reportedly preparing for a potential sale of its orthopedics unit, DePuy Synthes, as it advances plans to separate the business.

In 2011, the medtech giant acquired DePuy Synthes for a massive $21.3 billion.

In October 2025, Johnson & Johnson said it plans to separate its Orthopedics business to enhance the strategic and operational focus.

Johnson & Johnson said it is targeting completion within 18 to 24 months.

Don’t Miss:

**Explore the Fire-Safe Energy Storage Company With $185M in Contracted Revenue**

**Before the IPO: ****How One Company Quietly Locked Up 500+ Iconic Character Rights**

Bloomberg noted that at the time, CFO** Joseph Wolk** said the company hadn’t yet decided how to enact the split but said it was preparing for the possibility of a spinoff, the most time-consuming and resource-intensive approach. He said Johnson & Johnson was “open to ideas that others might have,” including a sale or another transaction if it resulted in greater value.

Bank of America analyst wrote, “The exit makes sense, in our view; in the long-term, DePuy Synthes should benefit from improved focus and become more competitive.”

Buyout firms have already shown interest. Bloomberg Intelligence estimates the unit could be worth about $20 billion, and $28 billion including debt.

Potential Buyers and Unit Performance

Johnson & Johnson is currently preparing financial materials ahead of meetings with potential buyers in the coming weeks, the Bloomberg report noted. Several large private equity firms are reportedly considering joint bids.

See Also: Blue-chip art has historically outpaced the S&P 500 since 1995, and fractional investing is now opening this institutional asset class to everyday investors.

DePuy Synthes, which produces hip and knee replacement devices and generated $9.3 billion in annual sales, may also attract interest from strategic medical device players.

Discussions remain preliminary, and a transaction is not assured.

Johnson & Johnson reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, up 20.6% year over year, beating the consensus of $2.44.

The company expects 2026 sales of $99.50 billion-$100.5 billion compared to the consensus of $98.89 billion.

**Read Next: **

**Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — ****Investors Can Still Get In at $0.85/Share**

**This Under-$1 Pre-IPO AI Company Is Still Open to Retail Investors —**** Learn More**

Image via Shutterstock

Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today’s competitive market.

Story Continues  

Get the latest stock analysis from Benzinga:

TESLA (TSLA): Free Stock Analysis Report

This article J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push originally appeared on Benzinga.com

Terms and Privacy Policy

Privacy Dashboard

More Info